EUVIMEDEUVIMED entdecken
Crossref

Loganic acid protects against ulcerative colitis by inhibiting TLR4/NF-κB mediated inflammation and activating the SIRT1/Nrf2 anti-oxidant responses in-vitro and in-vivo

Arun N Prakash, Neethu Prasad, Eswara Rao Puppala, Samir Ranjan Panda, Siddhi Jain, V Ravichandiran, Meenakshi Singh, V G M Naidu

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.110585 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Arun N Prakash und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, Assam 781101, India. Hauptthemen laut MEDLINE: Colitis, Ulcerative. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ulcerative colitis (UC) is an idiopathic, chronic disorder of the intestines characterized by excessive inflammation and oxidative stress. Loganic acid (LA) is an iridoid glycoside reported to have antioxidant and anti-inflammatory properties. However, the beneficial effects of LA on UC are unexplored yet. Thus, this study aims to explore the potential protective effects of LA and its possible mechanisms. In-vitro models were employed using LPS-stimulated RAW 264.7 macrophage cells, and Caco-2 cells, whereas an in-vivo model of ulcerative colitis was employed using 2.5% DSS in BALB/c mice. Results indicated that LA significantly suppressed the intracellular ROS levels and inhibited the phosphorylation of NF-κB in both RAW 264.7 and Caco-2 cells, contrarily LA activated the Nrf2 pathway in RAW 264.7 cells. In DSS-induced colitis mice, LA significantly alleviated the inflammation and colonic damage by decreasing the pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, and IFN-γ), oxidative stress markers (MDA, and NO), and also expression levels of various inflammatory proteins (TLR4 and NF-кB) which was evidenced by immunoblotting. On the contrary, the release of GSH, SOD, HO-1, and Nrf2 were profoundly increased upon LA treatment.Subsequently, molecular docking studies showed that LA interacts with active site regions of target proteins (TLR4, NF-κB, SIRT1, and Nrf2) through hydrogen bonding and salt bridge interaction. The current findings demonstrated that LA could exhibit a protective effect in DSS-induced ulcerative colitis through its anti-inflammatory and anti-oxidant effects via inactivating the TLR4/NF-κB signaling pathway and activating the SIRT1/Nrf2 pathways.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeHumansMiceAnimalsNF-kappa BAntioxidantsNF-E2-Related Factor 2Toll-Like Receptor 4Sirtuin 1Molecular Docking SimulationCaco-2 CellsInflammationAnti-Inflammatory AgentsDextran SulfateIridoids

Stichwörter der Autor:innen

Anti-inflammatoryAnti-oxidantIn-vitro and in-vivoLoganic acidUlcerative colitis

Substanzen

NF-kappa BAntioxidantsNF-E2-Related Factor 2Toll-Like Receptor 4Sirtuin 1Anti-Inflammatory AgentsDextran Sulfateloganic acidIridoidsSIRT1 protein, human

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, Assam 781101, India.
  • Department of Natural Products, National Institute of Pharmaceutical Education and Research (NIPER)-Kolkata, West Bengal 700054, India.
  • Centre for GMP Extraction Facility, Sponsored by Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, Assam 781101, India. Electronic address: meena24kshi@gmail.com.
  • Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, Assam 781101, India; Centre for GMP Extraction Facility, Sponsored by Department of Biotechnology,…

Zitieren

APA

Prakash, A. N., Prasad, N., Puppala, E. R., Panda, S. R., Jain, S., Ravichandiran, V., Singh, M., & Naidu, V. G. M. (2023). Loganic acid protects against ulcerative colitis by inhibiting TLR4/NF-κB mediated inflammation and activating the SIRT1/Nrf2 anti-oxidant responses in-vitro and in-vivo. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110585

Vancouver

Prakash AN, Prasad N, Puppala ER, Panda SR, Jain S, Ravichandiran V, et al. Loganic acid protects against ulcerative colitis by inhibiting TLR4/NF-κB mediated inflammation and activating the SIRT1/Nrf2 anti-oxidant responses in-vitro and in-vivo. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110585

BibTeX
@article{Prakash2023,
  author = {Prakash, Arun N and Prasad, Neethu and Puppala, Eswara Rao and Panda, Samir Ranjan and Jain, Siddhi and Ravichandiran, V and Singh, Meenakshi and Naidu, V G M},
  title = {Loganic acid protects against ulcerative colitis by inhibiting TLR4/NF-κB mediated inflammation and activating the SIRT1/Nrf2 anti-oxidant responses in-vitro and in-vivo},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.110585}
}
Kostenlos starten →